Lymphoma, Large B-Cell, Diffuse: all 1,432 studies
Page 12 of 15. Open to participants first (359), then studies with results posted, then the rest; newest registration first within each.
- A Feasibility Study of Gallium-68 Citrate PET to Detect Aberrant MYC Proto-Oncogene, BHLH Transcription Factor (MYC) Protein Expression in Diffuse Large B-Cell LymphomaWithdrawnNCT02776891Phase 2
- A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated CD20(Cluster of Differentiation Antigen 20)-Positive DLBCL PatientsStatus unknownNCT02772822Phase 3
- Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell LymphomaStatus unknownNCT02767674Phase 3
- CyBeR Association in Relapsed/Refractory DLBCLStatus unknownNCT02758925Phase 2
- A Clinical Trial of Buparlisib and Ibrutinib in LymphomaCompletedNCT02756247Phase 1
- Chidamide Plus R-CHOP in Elderly DLBCLStatus unknownNCT02753647Phase 2
- Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell LymphomaStatus unknownNCT02753062Phase 2
- Reduced Chemotherapy in Low Risk DLBCLStatus unknownNCT02752815Phase 4
- An Evaluation AZD2014 Alone and in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell LymphomaCompletedNCT02752204Phase 2
- Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCLStatus unknownNCT02747732Phase 2
- Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in LymphomaWithdrawnNCT02743546Phase 1
- the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)Status unknownNCT02737085Phase 1/2
- A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)Active, not recruitingNCT02734771Phase 2
- Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell LymphomaStatus unknownNCT02733380Phase 2
- Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell LymphomaStatus unknownNCT02728882Not applicable
- Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma PatientsStatus unknownNCT02721407Phase 1
- Utility Study in Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT02708732
- A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin LymphomaTerminatedNCT02702141Phase 1
- A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell LymphomasTerminatedNCT02700022Phase 1
- Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/LymphomaStatus unknownNCT02685670Phase 1/2
- Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell LymphomaCompletedNCT02670616Phase 2
- Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell LymphomaCompletedNCT02660710Phase 2
- Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)WithdrawnNCT02653989Phase 2
- Memory-enriched CAR-T Cells Immunotherapy for B Cell LymphomaStatus unknownNCT02652910Phase 1/2
- Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin LymphomaCompletedNCT02652715Not applicable
- CD34+ Selected ASCT for Aggressive LymphomasCompletedNCT02646098Phase 2
- Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)CompletedNCT02631044Phase 1
- Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaWithdrawnNCT02623920Phase 2
- Safety and Efficacy Study of CNOP Chemotherapy in Diffuse Large B Cell LymphomaWithdrawnNCT02595242Phase 1
- Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLLCompletedNCT02580552Phase 1
- Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)Active, not recruitingNCT02570542Phase 2
- Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin LymphomaCompletedNCT02568553Phase 1
- Geriatric Assessments in Elderly Diffuse Large B-cell LymphomaCompletedNCT02555267
- MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)CompletedNCT02549651Phase 1
- NM-IL-12 (rHuIL-12) In Relapsed/Refractory Diffuse Large B- Cell Lymphoma (DLBCL) Undergoing Salvage ChemotherapyStatus unknownNCT02544724Phase 2
- A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCLStatus unknownNCT02542111Phase 2
- A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell LymphomaWithdrawnNCT02532192Phase 1
- High-dose Chemotherapy and ASCT or Consolidating Conventional Chemotherapy in Primary CNS LymphomaStatus unknownNCT02531841Phase 3
- Multicenter Prospective Registry Study of Diffuse Large B Cell LymphomaStatus unknownNCT02474550
- KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell LymphomaCompletedNCT02471911Phase 1
- A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell MalignanciesTerminatedNCT02454270Phase 1
- Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic TransplantationCompletedNCT02431988Phase 1
- R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell LymphomaStatus unknownNCT02428751Phase 3
- A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.CompletedNCT02417285Phase 1
- Study of Ofatumomab in Combination With ICE-chemotherapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)CompletedNCT02412267Phase 2
- Tumor-Specific Clonotype, Metabolic Profile, and PET/CT in Predicting Chemotherapy Response in Patients With Relapsed or Refractory Diffuse Large B-cell LymphomaCompletedNCT02405078Early Phase 1
- First-line Antibiotic Therapy for Early-stage HP(+) Gastric Pure DLBCLStatus unknownNCT02388581Phase 2
- Safety Study of SEA-CD40 in Cancer PatientsTerminatedNCT02376699Phase 1
- Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory DLBCL PatientsTerminatedNCT02374424Phase 2
- Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell TherapyCompletedNCT02374333Phase 1
- Prospective Data Collection of Elderly Patients With DLBCL Receiving at the Time of Diagnosis VGMStatus unknownNCT02364050
- A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed LymphomaCompletedNCT02343536Phase 1
- Clinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell LymphomaCompletedNCT02340936Phase 1/2
- A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCLTerminatedNCT02323230Phase 2
- Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell MalignanciesCompletedNCT02290951Phase 1
- Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin LymphomaWithdrawnNCT02281279Phase 1/2
- Infusion of Allogeneic, 3rd Party CD19-specific T CellsWithdrawnNCT02274506Phase 1
- Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic CancerCompletedNCT02240719Phase 1
- Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi SarcomaWithdrawnNCT02229981Phase 1/2
- Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Active, not recruitingNCT02227251Phase 2
- A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell LymphomaCompletedNCT02220842Phase 1
- Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell LymphomaCompletedNCT02219737Phase 1
- Safety Study of SGN-CD70A in Cancer PatientsCompletedNCT02216890Phase 1
- Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive LymphomasCompletedNCT02181218Phase 1
- CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaTerminatedNCT02168907Phase 1
- Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic LeukemiaActive, not recruitingNCT02153580Phase 1
- Carfilzomib Plus Belinostat in Relapsed/Refractory NHLCompletedNCT02142530Phase 1
- Yoga Fatigue StudyTerminatedNCT02134782Not applicable
- Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+CompletedNCT02128061Phase 3
- Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV InfectionTerminatedNCT02109224Phase 1
- Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell LymphomaCompletedNCT02086604Phase 1
- Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND)Status unknownNCT02060656Phase 2
- Epstein-Barr Virus Status in Diffuse Large B Cell LymphomaCompletedNCT02060435
- R-CHOP Alone vs. R-CHOP Plus Radiotherapy for Localized CD20+ DLBCLWithdrawnNCT02054559Phase 3
- Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin LymphomaActive, not recruitingNCT02051257Phase 1
- Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular LymphomaTerminatedNCT02031419Phase 1
- Clinical Trial to Evaluate R-COMP Versus R-CHOP in Newly Diagnosed Patients With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIbCompletedNCT02012088Phase 2
- A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.CompletedNCT01991184Phase 1
- Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With DLBCL: a Phase II Multicenter Study of the FILStatus unknownNCT01990144Phase 2
- Bortezomib Maintenance in High Risk DLBCLStatus unknownNCT01965977Phase 2
- Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological DiseasesTerminatedNCT01962636Not applicable
- Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell TransplantCompletedNCT01959477Early Phase 1
- Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaActive, not recruitingNCT01955499Phase 1
- Treatment of Diffuse Large B Cell LymphomaStatus unknownNCT01949818Phase 4
- Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic LeukemiaTerminatedNCT01944943Phase 2
- Safety Study of CPX-351 in Children With Relapsed Leukemia or LymphomaCompletedNCT01943682Phase 1
- Carfilzomib Consolidation Therapy After Autologous Stem Cell Transplantation (ASCT) for Mantle Cell Lymphoma (MCL), T-cell Lymphoma (TCL), and Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT01926665Phase 1
- Dose-adjusted EPOCH-R in MYC Positive DLBCLTerminatedNCT01914718Phase 2
- Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell LymphomasCompletedNCT01897012Phase 1
- The Use of PET for the Early Response Evaluation in Patients With Diffuse Large B-cell Lymphoma.Status unknownNCT01865058
- Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19Status unknownNCT01864889Not applicable
- Treatment for Advanced B-Cell LymphomaCompletedNCT01859819Phase 2
- Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell LymphomaCompletedNCT01854606Phase 1
- Rituximab-HyperCVAD (R-HCVAD) Alternating With Rituximab-Methotrexate-Cytarabine- (R-MC) in Newly Diagnosed Patients With Diffuse Large B-Cell Lymphoma With MYC-Rearrangement.WithdrawnNCT01854372Phase 2
- R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3BStatus unknownNCT01852435Phase 3
- Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHLCompletedNCT01851551Phase 1/2
- Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.CompletedNCT01848132Phase 2
- Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell LymphomaCompletedNCT01846390Phase 1
- Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute LeukemiaCompletedNCT01842672Phase 1/2
- Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase TherapyActive, not recruitingNCT01829958Not applicable